WuXi XDC Cayman is to provide Ona Therapeutics with an exclusive global licence to its WuXiTecan-2 platform to develop an ADC candidate.

The deal reflects a growing interest from big pharma in the compounds that bridge the gap between small molecules and biologics.

The HHS appoints these leadership positions as it looks to “reform” the FDA, which has recently faced a high turnover in leadership.

Novo will harness Anthropic’s AI assistant Claude to accelerate research and development (R&D) activities, as the drugmaker looks to regain its once-dominant position at the fro ...

Sling is racing to market the first oral IGF-1R blocker, which would likely provide competition to Amgen’s Tepezza.

Definium Therapeutics plans to submit an NDA for LSD-based psychedelic, DT120 in generalised anxiety disorder (GAD) during H1 2027.

At ERS 2026, investigators presented their findings exploring the link between BMI and severe asthma outcomes in response to biologics.

Thoracic oncologists previously touted the potential of Bayer's Hyrnuo in HER2-mutant NSCLC in both the first- and second-line settings.

Share prices tumbled last week after a key asset from Novartis’ $12bn Avidity deal fumbled in a Phase III trial.

The FDA has granted accelerated approval to AstraZeneca's Etcamah (camizestrant), used with a CDK 4/6 inhibitor, for breast cancer.

A survey of 175 pharma executives highlights an increasing reluctance to launch in lower-value markets, alongside a heightened focus on RWE.

ABEC is to open a new manufacturing facility in Wilson, North Carolina, US, expanding its network for biopharmaceutical process equipment.